BioSpace News Archive

Portfolio Expansion Ensures Dogs and Puppies 8 Weeks of Age and Older Receive Early, Broad-Spectrum Protection Against Fleas and Ticks

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2020 (3QFY20) and the first nine months of fiscal year 2020 (9moFY20), the period ended May 31, 2020.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2020 financial results on Thursday, July 30, 2020, at 7:30 a.m. Central Time.

Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX® for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.

efficacyAI, Inc. announced today that it has recently signed a license agreement with the Georgia Tech Research Corporation granting it exclusive rights to the use of a suite of algorithms called MedicascyAI.

Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances the anti-tumor activity of innate and adaptive immune cells Also, first publication of a regulatory mechanism of the CD28/B7 immune stimulatory pathway, identifying CD28 shedding as a potential novel target for cancer therapeutics MISGAV, Israel, July 09, 2020 (GLOBE NEWSWIRE) -- Biond Biologics Ltd. (“Biond” or the “Company”), a privately-held biopharmaceuti

AppliedVR, a pioneer advancing the next generation of digital medicine, today announced results from the first randomized controlled trial (RCT), evaluating virtual-reality-based (VR) therapy for self-management of chronic pain at home.

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update. Preliminary Unaudited Results f

DRADS Capital announced its investment in ROKIT Healthcare Inc., a South Korean biotechnology company developing innovative 4D bioprinting techniques and applications, in its Series C funding round of undisclosed amount.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has appointed Steve Edgett as a Strategic Advisor. Mr. Edgett will act as a special advisor to the CEO and the Board of Directors with a mandate to advise on strategic and capital markets aspects of the Company’s activities and to aid in the advancement of our key programs: ARDS-003, QIXLEEF™ and CAUMZ™.